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The objective of this study was to compare the effectiveness of the collagen-gelatin sponge (CGS) with that of the collagen sponge
(CS) in dermis-like tissue regeneration. CGS, which achieves the sustained release of basic fibroblast growth factor (bFGF), is a
promising material in wound healing. In the present study, we evaluated and compared CGSs and conventional CSs. We prepared
8mm full-thickness skin defects on the backs of rats. Either CGSs or CSs were impregnated with normal saline solution (NSS) or
7𝜇g/cm2 of bFGF solution and implanted into the defects. At 1 and 2 weeks after implantation, tissue specimens were obtained from
the rats of each group (𝑛 = 3, total 𝑛 = 24).Thewound area, neoepithelial length, dermis-like tissue area, and the number and area of
capillaries were evaluated at 1 and 2weeks after implantation.There were no significant differences in the CGSwithout bFGF andCS
groups. Significant improvements were observed in the neoepithelial length, the dermis-like tissue area, and the number of newly
formed capillaries in the group of rats that received CGSs impregnated with bFGF.The effects on epithelialization, granulation, and
vascularization of wound healing demonstrated that, as a scaffold, CGSs are equal or superior to conventional CSs.
1. Introduction
We developed a bilayered acellular artificial dermis (Pelnac,
Gunze Co. Ltd., Ayabe, Japan) consisting of an upper silicone
sheet and a lower collagen sponge (CS) [1]. After the CS is
grafted onto a full-thickness skin defect, fibroblasts and new
capillaries spread throughout the lower layer of the sponge.
New collagen fibers are synthesized by the penetration of
fibroblasts and the collagen sponge biodegrades and are
gradually replaced with regenerated dermis-like tissue within
a period of 2-3weeks [1, 2]. Artificial dermis has been used for
the treatment of full-thickness skin defects caused by burns,
in the waiting period for tumor excision, and for the treat-
ment of intractable ulcers formore than 10 years [3].However,
until the capillaries infiltrate the collagen sponge and the
vascular network is formed, the artificial dermis exposes
the patient to a high risk of infection [4]. It is therefore
difficult to apply artificial dermis to chronic ulcers, such as
decubitus, diabetic, and leg ulcers [4]. Basic FGF, which was
identified in 1974, promotes the proliferation of fibroblasts
and the formation of capillaries and accelerates tissue regen-
eration [5–9]. In Japan, human recombinant bFGF (Fibrast
Spray, Kaken Pharmaceutical Co., Ltd., Tokyo, Japan) has
been available since 2001, and its clinical effectiveness has
been verified [7]. In combination with bFGF, artificial dermis
has been reported to accelerate dermis-like tissue formation
[10]. However, bFGF is rapidly diffused and inactivated
after application in vivo [11]. To overcome this disadvantage,
we developed a CGS that contains a 10 wt% concentration
of acidic gelatin which is capable of sustaining positively
charged growth factors, such as bFGF, via the formation
of ion complexes between bFGF and gelatin [4, 12, 13]. In
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our previous study, we reported that CGSs impregnated
with bFGF (7𝜇g/cm2) accelerated neovascularization and
wound healing with less contraction on the backs of mice,
in the femoral trochanters of diabetic mice, and in the
palatal mucosa of dogs [12, 14]. We also reported that
CGSs impregnatedwith bFGF accelerated the healing process
of chronic ulcers in the first-in-human clinical trial [13].
However, the equivalence of CS and CGS as a scaffold has
not yet been confirmed. Therefore, in this study, the effects
of the application of CSs and CGSs with and without bFGF
were evaluated and compared using the same full-thickness
skin defects in rats in terms of dermis-like tissue formation,
epithelization, and capillary formation.
2. Material and Methods
2.1. Animals andOperations. Theanimals weremaintained at
the Bioscience Department of KAC Co., Ltd. (Rittou, Japan).
The number of animals used in this study was kept to a
minimum, and all possible efforts were made to reduce their
suffering in compliance with the protocols established by the
Animal Research Committee Determination of KAC.
2.2. Preparation of CS and CGS. We used conventional CSs
(Pelnac, Gunze Co. Ltd., Ayabe, Japan) and CGSs produced
according to the procedure shown in our previous study
[1, 4]. Briefly, a collagen and gelatin solution with a gelatin
(isoelectric point (IEP): 5.0) concentration of 10 wt% of
the total solute was prepared and freeze-dried. A silicone
solution (Shin-Etsu Chemical, Tokyo, Japan) was used to
make silicone sheets of 200𝜇m in thickness containing a
polyester mesh, and the top of the CGS was covered with the
silicone sheet.
2.3. The Impregnation of CS and CGS with NSS and bFGF.
We prepared CSs and CGSs of 8mm in diameter on a dish
(NUNC DISH 100X20 VENTS NUNCLON D SI (Thermo
Fisher Scientific Inc., Yokohama, Japan)). We previously
reported that CGSs impregnated with bFGF at doses of
7 𝜇g/cm2 and 14 𝜇g/cm2 accelerated the healing processes
in mice and diabetic mice, respectively [12]. We there-
fore adopted the 7 𝜇g/cm2 dosage in the present study. At
the time of impregnation, 500𝜇g of human recombinant
bFGF, in the form of a dry powder (Fibrast Spray; Kaken
Pharmaceutical, Tokyo, Japan), was dissolved in 7.14mL of
normal saline solution (NSS, Otsuka Pharmaceutical Co.,
Ltd., Tokyo, Japan), and 70 𝜇g/mL (3.5 𝜇g/50 𝜇L) of bFGF
solution was prepared. Fifty microliters of NSS was applied
to CSs or CGSs in the NSS group; the same amount of
bFGF solution was applied to impregnate CSs or CGSs with
7 𝜇g/cm2 of bFGF. They were incubated for 30 minutes at
room temperature. Four experimental groups were generated
as follows: (1) CSs impregnated with NSS (CS-NSS group);
(2) CGSs impregnated with NSS (CGS-NSS group); (3) CSs
impregnated with bFGF (7 𝜇g/cm2) (CS-bFGF group); and
(4) CGSs impregnated with bFGF (7𝜇g/cm2) (CGS-bFGF
group). Eighteen samples were taken from each experimental
group.
2.4. The Implantation of CS and CGS into Full-Thickness
Skin Defects in Rats. We prepared seven-week-old male rats
(𝑛 = 24, Slc: Wistar, SLC Japan Co., Ltd., Fukuoka, Japan).
All of the rats had their backs and abdomens shaved and
depilated under anesthesia by the intraperitoneal injection of
pentobarbital (30mg/kg) (Somnopenthyl, Kyoritsu Seiyaku
Corporation, Tokyo, Japan) and the inhalation of isoflurane
(Escain Pfizer Japan Inc., Tokyo, Japan).Three full-thickness
skin defects measuring 8mm in diameter were created in
the back (longitudinally) of each rat, and 9 samples from
three animals were included in each group. Therefore, each
group had 9 samples that were adequate for the statistical
analysis. Three full-thickness skin defects were created at an
interval of 16mm using an 8mm diameter skin punch biopsy
tool (Kai Industries, Gifu, Japan), a scalpel, and scissors. The
panniculus carnosus was preserved. CSs or CGSs (𝑛 = 18
in each group) impregnated with either NSS or bFGF were
implanted into three skin defects created on the backs of each
rat (6 rats in each group). The CSs and CGSs were sutured to
themarginal skin using 5-0 nylon sutures (Medical U&A Inc.,
Osaka, Japan), covered with gauze, and fixed in place with
adhesive tape (SILKYTEX, Alcare Co. Ltd., Tokyo, Japan).
2.5. The Assessments of the Wound Area and the Neoepithelial
Length. At 1 and 2 weeks after implantation, 3 rats per
group were sacrificed via the inhalation of carbon dioxide.
After the removal of the silicone sheets, the wounds (𝑛 =
9) were photographed, and the wound area was measured
using the Image J software program (version 1.47, National
Institute of Health, USA). The wound area was expressed as
the percentage of the original wound area. Skin specimens,
including the implanted CSs and CGSs, were harvested using
scalpels and scissors and were sectioned axially at the center
of each specimen. The specimens were then fixed with 20%
formalin fluid (Mildfolm, Wako Pure Chemical Industries,
Osaka, Japan), paraffin-embedded, and sliced into 4 𝜇m thick
sections. The sections were then stained with hematoxylin
and eosin (H&E). Using a fluorescence microscope (Biorevo
BZ-9000; Keyence, Co., Osaka, Japan), the length of the
neoepithelium, from the innermost hair root of the marginal
skin to the end of the neoepithelium, was measured on
each side of each cross-sectional area in each specimen at
a magnification of ×100. The sum of the lengths of the
epithelium was evaluated on both sides.
2.6. Evaluation of the Area of Dermis-Like Tissue. Azan stain-
ing sections were used to assess the newly formed dermis-like
tissue. Azan stain is a complex staining method for general
histology. Nuclei are stained bright red with azocarmine G
and connective tissues, such as collagen fibers, are stained
blue with aniline blue or orange G.The area of newly formed
dermis-like tissue was measured by using the image stitching
function of a fluorescence microscope (Biorevo BZ-9000).
The lateral border of the regenerated area was determined
by the transitional boundary layer of the continuous parallel
structure of the dermis and the fragmental structure of
newly formed dermis-like tissue. The lower border of the
regenerated area was above the panniculus carnosus, and
the upper epithelium was not included in the measurement.
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Figure 1: The gross appearance of the full-thickness skin defects before CS and CGS implantation and wounds at 1 and 2 weeks after
implantation. The gross appearance of wounds in the CS-NSS (a), CGS-NSS (b), CS-bFGF (c), and CGS-bFGF (d) groups at 1 week after
implantation. The gross appearance of wounds in the CS-NSS (a󸀠), CGS-NSS (b󸀠), CS-bFGF (c󸀠), and CGS-bFGF (d󸀠) groups at 2 weeks after
implantation. Scale bar: 1000 𝜇m.
The area of newly formed dermis-like tissue was statistically
analyzed.
2.7. Evaluation of Newly Formed Capillaries in the Dermis-Like
Tissue. Immunohistological staining with von Willebrand
factor antigenwas performed to detect newly formed capillar-
ies in the dermis-like tissue. After deparaffinization and rehy-
dration, the sections were incubated in phosphate-buffered
saline (PBS Life Technologies Co. Japan, Tokyo, Japan)
with 0.1% trypsin (Vector Laboratories Inc., Burlingame,
GA, USA) for 15min at 37∘C for antigen retrieval. Anti-
von Willebrand factor rabbit polyclonal antibody (1 : 500
dilutions, Dako Japan Co., Tokyo, Japan) and EnVision+
Rabbit/HRP (Dako Japan Co., Tokyo, Japan) were used as
the secondary antibody. These sections were exposed to
DAB (3,3󸀠-diaminobenzidine-4HCL; Dako Japan Co., Tokyo,
Japan) for 2min at room temperature. Counterstaining was
performed with hematoxylin.
In each section, the newly formed capillaries were
counted and the area of newly formed capillaries was mea-
sured manually in the regenerated area at a magnification
of ×200, using the measurement module of a fluorescence
microscope (Biorevo BZ-9000).
2.8. Statistical Analysis. All of the data were expressed as the
mean + standard error (SE) and were analyzed using Tukey’s
significant difference test (Tukey Kramer test). 𝑃 values of
<0.05 were considered to indicate statistical significance.
3. Results
3.1. Wound Area. One animal died suddenly on the fifth day
due to unknown reasons.The gross appearance of thewounds






























Figure 2:The time course of the remainingwound area.Thewounds
were treated with CS-NSS, CGS-NSS, CS-bFGF, or CGS-bFGF at
1 and 2 weeks. At 1 and 2 weeks, the remaining wound area did
not differ among the groups to a statistically significant extent. At 2
weeks after implantation, the areas of the wounds in all of the groups
were significantly smaller than at 1 week (∗∗𝑃 < 0.01).
week after surgery, wound closure was not completed in any
of the four groups. At twoweeks after surgery, the wound area
was reduced and almost completely epithelized, and there
were no signs of pus, redness, or inflammation in any of the
four groups. The time course of the wound area is shown in
Figure 2. At two weeks after implantation, the wound area in
each groupwas significantly smaller than at 1week (𝑃 < 0.01).
There were no significant differences in wound areas of the
experimental groups at 1 and 2 weeks after surgery (Figure 2).









Figure 3: Light micrographs of full-thickness skin defects at 1 and 2 weeks after implantation. The wounds of the CS-NSS (a), CGS-NSS (b),
CS-bFGF (c), and CGS-bFGF (d) groups at 1 week.The wounds of the CS-NSS (a󸀠), CGS-NSS (b󸀠), CS-bFGF (c󸀠), and CGS-bFGF (d󸀠) groups
at 2 weeks.The black arrow with a solid line indicates a hair root which is the edge of the regenerated dermis-like tissue.The black arrow with
a broken line indicates the end of the neoepithelium. The neoepithelium is shown in the upper section as a black line. Scale bar: 500𝜇m.
3.2. Histological Assessment of the Neoepithelial Length. Light
microphotographs of the histological sections (H&E stain-
ing) at 1 and 2 weeks after implantation are shown in Figure 3.
The time course of the neoepithelial length is shown in
Figure 4. At two weeks, the neoepithelial length of the CGS-
bFGF group was significantly longer than that of the CS-NSS
and CGS-NSS groups at 1 week (𝑃 < 0.01 and 𝑃 < 0.05,
resp.). At two weeks, the neoepithelial length of the CGS-NSS
group was significantly longer than that of the CS-NSS group
at 1 week (𝑃 < 0.05). At two weeks after implantation, the
neoepithelial length of theCGS-bFGF groupwas significantly
longer than at 1 week (𝑃 < 0.01) (Figure 4).
3.3. Evaluation of the Area of Dermis-Like Tissue. The
regenerated area of dermis-like tissue at two weeks after
implantation is shown in Figure 5. The area of dermis-
like tissue in the CGS-bFGF group was significantly larger
than that in the CS-NSS and CS-bFGF groups (𝑃 < 0.01)
(Figure 6).
3.4. Evaluation ofNewly FormedCapillaries in theDermis-Like
Tissue. Light micrographs (von Willebrand factor antibody
staining), which were captured at 2 weeks after surgery, are
shown in Figure 7.The images show the center area of dermis-
like tissue specimens of 250 𝜇m in width and height. The
number of newly formed capillaries in the CGS-bFGF group
was significantly larger than that in theCS-NSS andCGS-NSS
groups (𝑃 < 0.05 and 𝑃 < 0.01, resp.) (Figure 8).
4. Discussion
In the present study we showed the efficacy of CGSs impreg-
nated with bFGF in the acceleration of the wound healing
process. We applied conventional CSs and CGSs (a novel

































Figure 4: The time course of the neoepithelial length. The wounds
of the CS-NSS, CGS-NSS, CS-bFGF, and CGS-bFGF groups at 1
and 2 weeks. At 2 weeks, the neoepithelial length of the CGS-bFGF
group was significantly longer than that of the CS-NSS and CGS-
NSS groups at 1 week (𝑃 < 0.01 and 𝑃 < 0.05, resp.). At 2 weeks, the
neoepithelial length of the CGS-NSS group was significantly longer
than that of the CS-NSS group at 1 week (𝑃 < 0.05). At 2 weeks after
implantation, the neoepithelial length of the CGS-bFGF group was
significantly longer than at 1 week (∗∗𝑃 < 0.01).
scaffold that allows for the sustained release of growth factors)
with and without bFGF to skin defects in rats and compared
the wound healing process. A significantly higher number of
capillaries were observed in the CGS-bFGF group; however,
the area of newly formed capillaries was not significantly
higher. This is probably because the number of specimens in
the CS-NSS group was small due to the unexpected death of
an animal. In other respects, CGSs impregnated with bFGF
(7 𝜇g/cm2) accelerated angiogenesis and dermis-like tissue
formation. This finding is in line with the findings of our
previous studies usingmice, diabeticmice, rabbits, and beagle
dogs [4, 12, 14]. We emphasize the formation of dermis-
like tissue in the healing process, because it accelerates
epithelization and prevents wound contracture [14]. Two
mechanisms are involved in the wound healing process:
wound contraction and epithelization. Murine wounds close
mostly throughwound contraction. In humans, wounds close
mostly through epithelization and wound contraction causes
scar contracture, decreasing the range of joint motion and/or
causing hypertrophic scarring.TheCGS-bFGF groupwas the
only group in which the neoepithelial length was observed
to grow from the first week to the second week. This growth
was the result of dermis-like tissue formation (Figure 4).
Conventional CSs have been used for the preparation of
dermis-like tissue, which prevent scar contracture. In this
point, the CGS-bFGF group showed the highest level of
dermis-like tissue formation, which indicates that CGSs
impregnated with bFGF can prevent wound contracture. In





Figure 5: Light micrographs (Azan staining) of the wounds at 2
weeks after implantation. The wounds of the CS-NSS (a), CGS-NSS
(b), CS-bFGF (c), and CGS-bFGF (d) groups. The area surrounded



























Figure 6: The comparison of the area of newly formed dermis-like
tissue at 2 weeks.The newly formed dermis-like tissue in the wounds
of the CGS-bFGF group was significantly larger than that of the CS-
NSS and CS-bFGF groups at 2 weeks (∗∗𝑃 < 0.01).
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Figure 7: Immunohistochemical staining (von Willebrand factor antibody) of newly formed capillaries at 2 weeks after implantation. The
wounds of the CS-NSS (a), CGS-NSS (b), CS-bFGF (c), and CGS-bFGF (d) groups. The open arrowheads indicate newly formed capillaries.
Scale bar: 50 𝜇m.
bFGFmainly to accelerate the healing of chronic ulcers (such
as diabetic foot ulcers and venous leg ulcers); however, the
present results indicate that, in addition to conventional
CSs, CGSs impregnated with bFGF can be used to promote
dermis-like tissue formation in the treatment skin defects.
CGS contains 10wt% of gelatin, which degrades more
easily than collagen. Another concern with regard to CGSs is
the possibility that its earlier degradation (in comparison to
CSs) after application in vivo is not a desirable characteristic
for a scaffold. However, we did not observe a significant
difference in the area of dermis-like tissue formation in the
CS-NSS and CGS-NSS groups and the CGS-bFGF group
showed the largest area of dermis-like tissue. These results
indicate that CGSs are equal to CSs in their efficacy as
scaffolds and that CGSs were not easily degraded in the
accelerated angiogenesis that occurred as a result of their
impregnation with bFGF.
Recently, skin substitutes containing living cells have been
reported to be effective in the treatment of chronic skin ulcers
[15–18]. We have reported that CSs cultured with autologous
fibroblasts and CGSs impregnated with bFGF were equally
effective in the treatment of diabetic ulcers [19]. We have not
evaluated the combination of CGSs with living cells; however,
it is thus expected that CGSs could be used in combination
with cells as well as CSs. Various types of cells, including stem
cells, have been used in the treatment of skin ulcers [20–22].
CGSs can achieve the sustained delivery of positively charged
growth factors and can also be used as a cell carrier. In the
future, other growth factors and cells will be developed. It is
possible that these growth factors and cells will be combined
with our CGS and used for treatment; thus, our CGS has
the potential to be used in the coming era of regenerative
medicine.
5. Conclusions
Wound healing after the treatment of rodent skin defects
with conventional CSs and CGSs with or without bFGF















































Figure 8: The comparison of the number and area of newly formed
capillaries at 2 weeks after implantation. The number of newly
formed capillaries in the wounds treated of the CGS-bFGF group
was significantly higher than that of the CS-NSS and CGS-NSS
groups (∗𝑃 < 0.05 and ∗∗𝑃 < 0.01, resp.).
was compared. The results showed that, as a scaffold, CGSs
can equal the efficacy of conventional CSs without bFGF.
Furthermore, we found that CGSs impregnated with bFGF
(7 𝜇g/cm2) accelerated the wound healing process which
indicates that they may supersede conventional CSs in the
clinical setting.
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